Why biotech?
The most event-driven sector in public markets, and the least crowded by retail money. Here is what makes it behave differently — and how to research it without a science degree.
What makes biotech different
Outcomes are binary
A drug either hits its endpoint or it doesn't; the FDA either approves or it doesn't. There is rarely a middle. For a company whose value sits in one or two assets, a single result can re-rate the whole business in a session — in either direction. Only 7.9% of drugs entering Phase 1 ever reach approval◆ (source: BIO / Informa / QLS, 2011–2020, opens in a new tab).
Complexity keeps the field small
Most retail investors avoid biotech because the science is intimidating. That means less competition and more inefficient pricing. If you can understand what's happening, you have an edge.
Big pharma has to buy growth
The industry is sitting on a record $2.1 trillion of M&A firepower◆ (source: EY Firepower M&A Report 2026, opens in a new tab) while facing a revenue gap of roughly $370 billion by 2032 as patents expire◆ (source: EY Firepower M&A Report 2026, opens in a new tab). They cannot research their way out of that in time, so they buy. Smaller biotechs with de-risked assets are the inventory.
The calendar is public
Unlike other sectors, biotech catalysts are announced months ahead. FDA decision dates, trial readouts, and conference presentations are all on public calendars. You can prepare.
What one readout is worth
Three scheduled, publicly known events, and what the market did with them. Two went one way. One went the other. That is the sector, honestly described.
Viking Therapeutics
Phase 2 obesity data
27 Feb 2024
VK2735 showed weight loss competitive with the market leaders. The readout was scheduled and public months in advance.
Seagen
Pfizer acquisition
13 Mar 2023
Bought for $43B for an antibody-drug conjugate platform — the pattern that $2.1T of pharma firepower keeps repeating.
Axovant Sciences
Phase 3 Alzheimer’s miss
26 Sep 2017
Intepirdine missed both co-primary endpoints. The mechanism had failed for others before; the trial design told you what to watch.
- ◆Viking Therapeutics (VKTX) reported topline Phase 2 VENTURE results for VK2735 on 27 February 2024; shares closed up roughly 121% on the session.
- ◆Pfizer agreed to acquire Seagen (SGEN) for $229 per share in cash — approximately $43B — on 13 March 2023, a ~32% premium to the prior close.
- ◆Axovant Sciences reported that intepirdine missed both co-primary endpoints in the Phase 3 MINDSET trial on 26 September 2017; shares fell roughly 70% the same day.
Individual examples selected to illustrate event-driven volatility in both directions. They are not representative of typical outcomes. Past performance does not guarantee future results. For educational purposes only.
Four ways people lose money here
Each of these is a research failure rather than a bad bet — which is why they're fixable.
The mistake
Buying after the news breaks
Why it hurts
By the time CNBC reports it, the stock has already moved. The opportunity is in positioning before catalysts.
How we help
Track upcoming FDA dates, trial readouts, and earnings. Our catalyst calendar shows you what's coming.
The mistake
Ignoring the science
Why it hurts
A "positive" trial result can still tank a stock if endpoints weren't met or safety signals emerged.
How we help
Our AI translates trial data into plain English so you understand what results actually mean.
The mistake
Not understanding cash runway
Why it hurts
Biotech companies burn cash. If they run out before key data, they dilute shareholders or go bankrupt.
How we help
We calculate cash runway and burn rate for every company so you know the financial risk.
The mistake
Treating all biotechs the same
Why it hurts
A Phase 1 company is pure speculation. A commercial-stage company is a different risk profile entirely.
How we help
Our pipeline analysis shows exactly where each drug is in development and what it means for risk.
The vocabulary, in one page
Every term below shows up in the filings and press releases that move these stocks. Worth a bookmark.
Phase 1
First testing in humans, focused on safety in small groups (20-100 people). About 52% of programmes advance to Phase 2.
Phase 2
Tests effectiveness and side effects in larger groups (100-300). About 29% advance to Phase 3 — the hardest gate in development.
Phase 3
Large-scale testing (1,000-3,000+) to confirm effectiveness. About 58% go on to a regulatory filing.
FDA Approval
Regulatory green light to sell the drug. Can take 6-12 months after Phase 3 data submission.
PDUFA Date
Prescription Drug User Fee Act date. The FDA's deadline to make an approval decision. Major catalyst.
AdCom
Advisory Committee meeting. Expert panel that recommends (or not) approval. Can move stocks 20%+.
NDA/BLA
New Drug Application / Biologics License Application. The formal request for FDA approval.
Breakthrough Designation
FDA fast-track status for drugs treating serious conditions. Speeds up development and review.
Primary Endpoint
The main measurement a trial must hit to be considered successful. Miss this = stock drops.
p-value
Statistical significance measure. p<0.05 means results are likely real, not random chance.
rNPV
Risk-adjusted Net Present Value. Values pipeline drugs by discounting for probability of failure.
Peak Sales
Estimated maximum annual revenue a drug could generate. Key input for valuation models.
Now put it to work
You now know what to look for. FuzeBio finds it for you — on any biotech, in seconds.